Enhancing encapsulation of filarial antigen thioredoxin in nano-liposomes: The role of lecithin composition.

Background And Purpose: Lymphatic filariasis is a debilitating infectious disease prevalent in endemic areas, necessitating the development of an effective vaccine for eradication. Although recombinant vaccine candidates have been deemed safe, they often fail to provide sufficient protection, which can be overcome by encapsulating them in nano-liposomes. In this study, we have optimised the liposomal composition for enhanced stability and encapsulation of filarial antigen thioredoxin (Bm-TRX).

Immunomodulatory effects of chitosan nanoparticles as vaccine delivery agent against lymphatic filariasis through mucosal immunization.

Lymphatic filariasis is a parasitic disease caused by nematodes affecting millions of individuals in the tropical region. The complex life cycle of the filarial parasite eludes protective measures such as chemotherapy and vector control. Vaccination through recombinant proteins stands as one of the safe and most effective methods.

In silico, in vitro antimicrobial and antimycobacterial evaluation of newly synthesized 2r, 6c-diaryl-3t-methylpiperidin-4-one arylsulphonylhydrazones.

Eight 2r,6c-diaryl-3t-methylpiperidin-4-one arylsulphonylhydrazones 4(a-d) and 5(a-d) was synthesized by the condensation of benzenesulphonylhydrazide (2) or p-toluenesulphonylhydrazide (3) with 2r,6c-diaryl-3t-methylpiperidin-4-ones 1(a-d). The structural and molecular confirmations of the synthesized hydrazones were interpreted using 1D, 2D NMR spectra and CHNS analysis. The in silico studies of synthesized compounds 4(a-d) and 5(a-d) against b-ketoacyl-ACP-synthase III (FabH) indicated excellent anti-tubercular efficacy.

Advances of Inorganic Materials in the Detection and Therapeutic Uses against Coronaviruses.

Coronaviruses (CoVs) are enveloped viruses with particle-like characteristics and a diameter of 60-140 nm, positively charged, and single-stranded RNA genomes, which caused a major outbreak of human fatal pneumonia in the beginning of the 21st century. COVID-19 is currently considered a continuous potential pandemic threat across the globe. Therefore, considerable efforts have been made to develop innovative methods and technologies for suppressing the spread of viruses as well as inactivating the viruses but COVID-19 vaccines are still in the development phase.

Immunoprophylaxis of multi-antigen peptide (MAP) vaccine for human lymphatic filariasis.

Human lymphatic filariasis, the parasitic disease caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi, and Brugia timori, is ranked as the second most complex clinical condition leading to permanent and long-term disability. The multiple antigen peptide (MAP) approach is an effective method to chemically synthesize and deliver multiple T and B cell epitopes as the constituents of a single immunogen. Here, we report on the design, chemical synthesis, and immunoprophylaxis of three epitopes that have been identified from promising vaccine candidates reported in our previous studies, constructed as MAP on an inert lysine core for human lymphatic filariasis in Jird model.

Immunopotentiating nano-chitosan as potent vaccine carter for efficacious prophylaxis of filarial antigens.

Lymphatic filariasis (LF), a morbid vector-borne parasitic infection affects millions in tropical areas. Complete eradication can only be achieved by the development of a potent vaccine. Among the various filarial antigens that have been characterized, antigens Brugia malayi thioredoxin (TRX) and abundant larval transcript (ALT) have produced recognizable level of protection in Jirds, thereby evidenced to be good vaccine candidates.